There are some skin conditions we're very familiar with: spots during adolescence, allergic rashes, sunburn. But others are ...

Phymatous rosacea: The skin thickens and becomes bumpy, particularly on the nose, which may cause it to enlarge. Ocular rosacea: The eyes and eyelids sting and become inflamed, watery, and bloodshot.

and ocular manifestations. Among the more recently approved treatments for rosacea — and among products and drug indications under study — “notice there’s a paucity of antibiotics ...

Patients with rosacea and skin of color are more likely to have severe disease phenotypes when compared with White patients with rosacea.

Tarsus Pharmaceuticals sees growth with Xdemvy's $180M sales in 2024. Read this article to know what makes TARS stock a BUY for growth investors.

Continued to advance a robust pipeline. Pursuing the next potentially transformative category in eye care – Ocular Rosacea a highly prevalent and underserved eye disease with no FDA-approved ...

One additional area you might not be thinking about but should be is eye health. Like other significant systems in the body, ...

A Phase II study for ocular rosacea is set to begin in late 2025, with data expected in 2026. Tarsus aims to expand physician education to identify Demodex blepharitis in broader patient categories.